An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Ibrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Janssen Biotech
- 01 Feb 2018 Status changed from active, no longer recruiting to completed.
- 20 Sep 2017 Planned End Date changed from 31 Jul 2017 to 29 Sep 2017.
- 20 Sep 2017 Planned primary completion date changed from 31 Jul 2017 to 29 Sep 2017.